Dynastat

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Bipacksedel Bipacksedel (PIL)
05-03-2024
Produktens egenskaper Produktens egenskaper (SPC)
05-03-2024

Aktiva substanser:

parecoxib sodium

Tillgänglig från:

Pfizer Europe MA EEIG

ATC-kod:

M01AH04

INN (International namn):

parecoxib

Terapeutisk grupp:

Coxibs, Antiinflammatory and antirheumatic products

Terapiområde:

Pain, Postoperative

Terapeutiska indikationer:

For the short-term treatment of postoperative pain in adults.,

Produktsammanfattning:

Revision: 32

Bemyndigande status:

Authorised

Tillstånd datum:

2002-03-22

Bipacksedel

                                52
B. PACKAGE LEAFLET
53
PACKAGE LEAFLET: INFORMATION FOR THE USER
DYNASTAT 40 MG POWDER FOR SOLUTION FOR INJECTION
parecoxib
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have further questions, ask your doctor or nurse.
-
If you get any side effects, talk to your doctor or nurse. This
includes any possible side effects
not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Dynastat is and what it is used for
2.
What you need to know before you use Dynastat
3.
How to use Dynastat
4.
Possible side effects
5.
How to store Dynastat
6.
Contents of the pack and other information
1.
WHAT DYNASTAT IS AND WHAT IT IS USED FOR
Dynastat contains the active substance parecoxib.
Dynastat is used for the short-term treatment of pain in adults after
an operation. It is one of a family
of medicines called COX-2 inhibitors (this is short for
_cyclo-oxygenase-2 inhibitors_
). Pain and
swelling are sometimes caused by substances in the body called
_prostaglandins_
. Dynastat works by
lowering the amount of these prostaglandins.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE DYNASTAT
DO NOT USE DYNASTAT
-
if you are allergic to parecoxib or any of the other ingredients of
this medicine (listed in section 6)
-
if you have had a serious allergic reaction (especially a serious skin
reaction) to any medicines
-
if you have had an allergic reaction to a group of medicines called
“sulfonamides” (e.g. some
antibiotics used to treat infections)
-
if you currently have a gastric or intestinal ulcer or bleeding in the
stomach or gut
-
if you have had an allergic reaction to acetylsalicylic acid (aspirin)
or to other NSAIDs (e.g.
ibuprofen) or to COX-2 inhibitors. Reactions might include wheezing
(bronchospasm), badly
blocked nose, itchy skin, rash or swelling of the face, lips or
tongue, other allergic reactions or
nasal polyps after taking these medicines
-
if you are more than 6 months p
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Dynastat 40 mg powder for solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_ _
Each vial contains 40 mg parecoxib (as 42.36 mg parecoxib sodium).
After reconstitution, the
concentration of parecoxib is 20 mg/ml. Each 2 ml of reconstituted
powder contains 40 mg of
parecoxib.
Excipient with known effect
This medicinal product contains less than 1 mmol sodium (23 mg) per
dose.
When reconstituted in sodium chloride 9 mg/ml (0.9%) solution,
Dynastat contains approximately
0.44 mmol of sodium per vial.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder for solution for injection (powder for injection).
White to off-white powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
For the short-term treatment of postoperative pain in adults.
The decision to prescribe a selective cyclooxygenase-2 (COX-2)
inhibitor should be based on an
assessment of the individual patient's overall risks (see sections 4.3
and 4.4).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose is 40 mg administered intravenously (IV) or
intramuscularly (IM), followed
every 6 to 12 hours by 20 mg or 40 mg as required, not to exceed 80
mg/day.
As the cardiovascular risk of COX-2 specific inhibitors may increase
with dose and duration of
exposure, the shortest duration possible and the lowest effective
daily dose should be used. There is
limited clinical experience with Dynastat treatment beyond three days
(see section 5.1).
Concomitant use with opioid analgesics
_ _
Opioid analgesics can be used concurrently with parecoxib, dosing as
described in the paragraph
above. In all clinical assessments parecoxib was administered at a
fixed time interval whereas the
opioids were administered on as needed basis.
Elderly
No dose adjustment is generally necessary in elderly patients (≥65
years). However, for elderly
patients weighing less than 50 kg, treatment should be initiated with
half the usual recommended dose
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 05-03-2024
Produktens egenskaper Produktens egenskaper bulgariska 05-03-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 13-07-2020
Bipacksedel Bipacksedel spanska 05-03-2024
Produktens egenskaper Produktens egenskaper spanska 05-03-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 13-07-2020
Bipacksedel Bipacksedel tjeckiska 05-03-2024
Produktens egenskaper Produktens egenskaper tjeckiska 05-03-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 13-07-2020
Bipacksedel Bipacksedel danska 05-03-2024
Produktens egenskaper Produktens egenskaper danska 05-03-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 13-07-2020
Bipacksedel Bipacksedel tyska 05-03-2024
Produktens egenskaper Produktens egenskaper tyska 05-03-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 13-07-2020
Bipacksedel Bipacksedel estniska 05-03-2024
Produktens egenskaper Produktens egenskaper estniska 05-03-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 13-07-2020
Bipacksedel Bipacksedel grekiska 05-03-2024
Produktens egenskaper Produktens egenskaper grekiska 05-03-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 13-07-2020
Bipacksedel Bipacksedel franska 05-03-2024
Produktens egenskaper Produktens egenskaper franska 05-03-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 13-07-2020
Bipacksedel Bipacksedel italienska 05-03-2024
Produktens egenskaper Produktens egenskaper italienska 05-03-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 13-07-2020
Bipacksedel Bipacksedel lettiska 05-03-2024
Produktens egenskaper Produktens egenskaper lettiska 05-03-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 13-07-2020
Bipacksedel Bipacksedel litauiska 05-03-2024
Produktens egenskaper Produktens egenskaper litauiska 05-03-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 13-07-2020
Bipacksedel Bipacksedel ungerska 05-03-2024
Produktens egenskaper Produktens egenskaper ungerska 05-03-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 13-07-2020
Bipacksedel Bipacksedel maltesiska 05-03-2024
Produktens egenskaper Produktens egenskaper maltesiska 05-03-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 13-07-2020
Bipacksedel Bipacksedel nederländska 05-03-2024
Produktens egenskaper Produktens egenskaper nederländska 05-03-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 13-07-2020
Bipacksedel Bipacksedel polska 05-03-2024
Produktens egenskaper Produktens egenskaper polska 05-03-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 13-07-2020
Bipacksedel Bipacksedel portugisiska 05-03-2024
Produktens egenskaper Produktens egenskaper portugisiska 05-03-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 13-07-2020
Bipacksedel Bipacksedel rumänska 05-03-2024
Produktens egenskaper Produktens egenskaper rumänska 05-03-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 13-07-2020
Bipacksedel Bipacksedel slovakiska 05-03-2024
Produktens egenskaper Produktens egenskaper slovakiska 05-03-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 13-07-2020
Bipacksedel Bipacksedel slovenska 05-03-2024
Produktens egenskaper Produktens egenskaper slovenska 05-03-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 13-07-2020
Bipacksedel Bipacksedel finska 05-03-2024
Produktens egenskaper Produktens egenskaper finska 05-03-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 13-07-2020
Bipacksedel Bipacksedel svenska 05-03-2024
Produktens egenskaper Produktens egenskaper svenska 05-03-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 13-07-2020
Bipacksedel Bipacksedel norska 05-03-2024
Produktens egenskaper Produktens egenskaper norska 05-03-2024
Bipacksedel Bipacksedel isländska 05-03-2024
Produktens egenskaper Produktens egenskaper isländska 05-03-2024
Bipacksedel Bipacksedel kroatiska 05-03-2024
Produktens egenskaper Produktens egenskaper kroatiska 05-03-2024
Offentlig bedömningsrapport Offentlig bedömningsrapport kroatiska 13-07-2020

Sök varningar relaterade till denna produkt

Visa dokumenthistorik